Please login to the form below

Not currently logged in
Email:
Password:

Taltz

This page shows the latest Taltz news and features for those working in and with pharma, biotech and healthcare.

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

The psoriasis market is becoming increasingly crowded, with newcomers Taltz from Eli Lilly and Tremfya from Johnson &Johnson demonstrating dramatically improved outcomes in the condition.

Latest news

  • Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial

    The clean sweep of primary and major secondary endpoints paints Taltz in a good light, although Lilly is yet to quantify how much better its drug was than Tremfya. ... Lilly brought Taltz to market using data showing it clears 90% of lesions in more than

  • Tremfya heads for filing in psoriatic arthritis Tremfya heads for filing in psoriatic arthritis

    Cosentyx. While Stelara remains in a solid second place behind runaway leader Humira, Cosentyx, AbbVie’s Skyrizi, Eli Lilly’s Taltz and Pfizer's Xeljanz also already approved in psoriatic arthritis. ... Taltz showed itself superior to Humira in

  • Lilly claims cluster headache first for CGRP drug Emgality Lilly claims cluster headache first for CGRP drug Emgality

    Emgality is an increasingly important product for Lilly’s growth now that another recent launch – IL-17 inhibitor Taltz (ixekizumab) for psoriasis – is facing increased competition from AbbVie’s recently-approved

  • Amgen buys Danish partner Nuevolution for $167m Amgen buys Danish partner Nuevolution for $167m

    a small-molecule interleukin-17a inhibitor that could rival injectable IL-17 biologics such as Novartis’ Cosentyx (secukinumab) and Eli Lilly’s Taltz (ixekizumab).

  • Pricing pressures peg back Lilly’s growth products Pricing pressures peg back Lilly’s growth products

    Lower-than-expected sales for psoriasis drug Taltz (ixekizumab) and Trulicity (dulaglutide) for diabetes were put down to increasing demand in the US market for rebates and discounts. ... IL-17 inhibitor Taltz grew 72% to $253m in the quarter, but

More from news
Approximately 6 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics